Group L Pcolumn Group Gp, L... Net Worth

The estimated Net Worth of Group L Pcolumn Group Gp, L... is at least $5.41 Milhão dollars as of 3 October 2019. Group L owns over 1,411,764 units of Constellation Pharmaceuticals Inc stock worth over $5,409,678 and over the last 5 years Group sold CNST stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Group L CNST stock SEC Form 4 insiders trading

Group has made over 1 trades of the Constellation Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Group bought 1,411,764 units of CNST stock worth $11,999,994 on 3 October 2019.

The largest trade Group's ever made was buying 1,411,764 units of Constellation Pharmaceuticals Inc stock on 3 October 2019 worth over $11,999,994. On average, Group trades about 1,411,764 units every 0 days since 2019. As of 3 October 2019 Group still owns at least 159,155 units of Constellation Pharmaceuticals Inc stock.

You can see the complete history of Group L stock trades at the bottom of the page.

Insiders trading at Constellation Pharmaceuticals Inc

Over the last 15 years, insiders at Constellation Pharmaceuticals Inc have traded over $36,293,867 worth of Constellation Pharmaceuticals Inc stock and bought 6,651,976 units worth $88,473,679 . The most active insiders traders include Peter Svennilson, Of The University Of Califo..., eAnthony B Evnin. On average, Constellation Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $4,934,940. The most recent stock trade was executed by Mark A Goldsmith on 4 March 2021, trading 14,987 units of CNST stock currently worth $509,408.

What does Constellation Pharmaceuticals Inc do?

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Complete history of Group L stock trades at Constellation Pharmaceuticals Inc

Constellation Pharmaceuticals Inc executives and stock owners

Constellation Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jigar Raythatha,
  President, Chief Executive Officer, Director
• Emma Reeve,
  Chief Financial Officer, Senior Vice President, Treasurer
• Scott Braunstein,
  Independent Director
• Mark Goldsmith,
  Independent Chairman of the Board
• Robert Tepper,
  Independent Director
• James Audia,
  Director
• Elizabeth Trehu,
  Independent Director
• Steven Hoerter,
  Independent Director
• Ronald Aldridge,
  IR Contact Officer
• Richard Levy,
  Independent Director
• Jeffrey Humphrey,
  Chief Medical Officer
• Karen Valentine,
  Chief Legal Officer, General Counsel
• Patrick Trojer,
  Chief Scientific Officer
• Group L Pcolumn Group Gp, L...,
  
• Group L Pcolumn Group Iii, ...,
  
• Group L Pgoeddel David V Sv...,
  
• Group L Pcolumn Group Iii, ...,
  
• Rock Ventures Lp Third Rock...,
  
• Advisors Llc Orbi Med Globa...,
  
• Of The University Of Califo...,
  
• Capital, Llc Casdin Partner...,
  
• Peter Svennilson,
  Director
• Ventures Ii, Lp Spur Capita...,
  
• Fund L.P.Topspin Biotech Fu...,
  
• Berg Ltd Mountain,
  10% owner
• Anthony B Evnin,
  Director
• Group L Pcolumn Group Gp, L...,
  
• Onco Ltd Precision,
  10% owner
• Venture Investments, Llc Al...,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Jerry A Hatfield,
  Sr. Vice President, Operations
• Michael John Hoffman,
  President and CEO
• Daniel Ingram,
  Senior V.P., Sales/Marketing
• James Ct Bolton,
  Senior Vice President
• James A Lewis,
  Director
• Frank J Mechura,
  Director
• Angus Smith,
  Director
• Donald P Deubel,
  SVP, Corporate Technologies
• Christopher Phelan,
  VP European Operations
• Walter Stanley Sobon,
  Executive VP and CFO
• David J Waksman,
  Senior Vice President
• Michael Dudley Mc Daniel,
  Director
• John P Neafsey,
  Director
• A Alexander Ii Taylor,
  Director
• Group L Pcolumn Group Gp, L...,
  
• Healthcare Capital Partners...,
  
• Adrian Senderowicz,
  Chief Medical Officer